alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 8,676–8,700 of 10,985 studies · free to read (page 348 of 440) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

FTD and ALS: a tale of two diseases

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Current Alzheimer research 2011-05-01

The first reports of disorders that in terms of cognitive and behavioral symptoms resemble frontotemporal dementia (FTD) and in terms of motor symptoms resemble amyotrophic lateral sclerosis (ALS) bring us back to the second half of the 1800s. Over the last 150 years, and especially in the last two decades, there has been growing evidence that FTD signs can be seen in patients primarily diagnosed with ALS, implying clinical overlap among these two disorders. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CNS inflammation and macrophage/microglial biology associated with HIV-1 infection

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2009-09-19

Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system (CNS) can result in neurological dysfunction with devastating consequences in a significant proportion of individuals with acquired immune deficiency syndrome. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

‘Good, honest food’: older adults' and healthcare professionals' perspectives of dietary influences and food preferences in older age in Ireland

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Human Nutrition and Dietetics 2023-07-31

A total of 47 adults aged 55+ years were recruited (50% male; 49% aged 60-69 years; 28% aged above 70 years), and 26 HCPs were involved, comprising dietitians (n = 8); geriatricians (n = 6); clinical therapists (n = 4); and nurses, pharmacists, catering managers and meal delivery service coordinators (n = 2 each). 5 key findings →

Participants: 47 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Socioeconomic disparities and nutritional aging: how food insecurity and financial hardship accelerate health decline in older adults

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in Nutrition 2026-06-08

This narrative review examines how socioeconomic disparities accelerate health decline in older adults. 1 key finding →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Disease-Specific Plan Switching Between Traditional Medicare and Medicare Advantage

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Permanente Journal 2019-11-21

Beneficiaries with a new diagnosis of Alzheimer disease and related dementias, hypertension, and psychiatric disorders had relatively high rates of switching into MA plans and low rates of switching out of MA plans. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Availability and use of telehealth services among patients with ADRD enrolled in traditional Medicare vs. Medicare advantage during the COVID-19 pandemic

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in Public Health 2024-02-27

There were 13,700 beneficiaries with full-year enrollment in MA (6,046) or TM (7,724), 518 with ADRD and 13,252 without ADRD. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Out of Pocket Costs for People with Dementia: A Comparison Across Insurance Types

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Innovation in Aging 2025-12-01

Among PWD with Medicaid, out-of-pocket costs for nursing homes and assisted living facilities were significantly higher (60%) compared to those TM (33%) and MA (30%). 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Diabetes 2018-06-22

For patients with serious comorbidities, diabetes management guidelines recommend more relaxed glycemic targets (glycosylated hemoglobin [HbA1c] <8-8.5% rather than <7%) and cautious use of agents known to cause hypoglycemia. 5 key findings →

Participants: 216,839 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Factors associated with delayed treatment initiation of oral anticoagulants among Medicare patients with atrial fibrillation

✓ Peer-reviewed alzhub usefulness score 41 out of 100. European Heart Journal 2023-11-01

In this study on Medicare patients with AF, Black race, low-income subsidy, and dual eligibility were found to be associated with delayed OAC initiation, suggesting potential disparities in the care of AF with timely OAC treatment. 5 key findings →

Participants: 446,441 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Decomposing Urban and Rural Disparities of Preventable ED Visits Among Patients With Alzheimer's Disease and Related Dementias: Evidence of the Availability of Health Care Resources

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of Rural Health 2020-07-02

Rural patients with ADRD had 1.23 higher adjusted odds (P < .001) of going to the ED for a preventable visit compared to urban counterparts. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neighborhood deprivation and mortality among people with Alzheimer's disease and related dementia

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer s Disease 2025-07-02

BackgroundThere are limited studies quantifying the extent to which neighborhood deprivation affects mortality in individuals living with Alzheimer's disease (AD) and AD-related dementias (AD/ADRD).ObjectiveTo quantify to what extent neighborhood deprivation affects adverse outcomes in individuals living with AD/ADRD.MethodsWe identified individuals with AD/ADRD using a 15% random sample of national Medicare fee-for-service beneficiaries. 1 key finding →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

County‐level indicators of education quality and brain imaging markers of neurodegeneration and vascular injury among racially and ethnically diverse middle‐aged and older adults

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2024-12-01

Higher teacher‐student ratio was associated with greater gray matter volume (β = 6.25, 95% CI: 1.57, 10.92) but was not associated hippocampal volume (β = ‐0.01, 95% CI: ‐0.14, 0.11), ventricular volume (β = ‐0.04, 95% CI: ‐0.13, 0.04), or white matter hyperintensity (β = ‐0.02, 95% CI: ‐0.31, 0.26) (Table 2). 5 key findings →

Participants: 450 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Nationwide Availability of and Enrollment in Medicare and Medicaid Dual-Eligible Special Needs Plans With Exclusively Aligned Enrollment

✓ Peer-reviewed alzhub usefulness score 41 out of 100. JAMA Health Forum 2024-10-18

Of 2 197 732 beneficiaries enrolled in D-SNPs in 2021, 881 736 (40.1%) were living in counties with aligned enrollment available and 251 305 (11.4%) enrolled. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Inequities in dementia diagnosis and care: insights from a universal health care system

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-12-01

Of the 193,834 community-dwelling people with a new diagnosis of dementia, around 20% belonged to each material deprivation category. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed